India, April 2 -- Men with early-stage metastatic prostate cancer may soon be able to postpone the debilitating side effects ...
New findings from VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM), published in ...
Join Tom and Mike as they share an important update on Tom's prostate cancer journey. In this video, they discuss Tom's ...
A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with ...
Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all ...
Based on the efficacy and safety data, Oric will advance the 400mg therapy to Phase III trials, with more treatment-emergent ...
ORIC Pharmaceuticals (ORIC) stock slides as the company posts early-stage trial data for its experimental prostate cancer ...
Belfast News Letter on MSN
Lisburn dad shares his prostate cancer journey to save lives
​A prostate cancer diagnosis turned life upside down for Lisburn man Stuart Rainey, bringing fear, uncertainty and countless ...
By partnering with other like-minded organizations to fund targeted RFAs throughout the year, ACS is able to invest in new ...
A randomized study in 58 men with limited metastatic prostate cancer found that PSMA therapy postponed the need for hormone ...
Shares of Oric Pharmaceuticals fell after the company said data from a phase 1b trial of a prostate cancer treatment showed that a larger dose led to higher rates of side effects. Shares were down 22% ...
In late March 2026, ORIC Pharmaceuticals reported Phase 1b data showing that rinzimetostat 400 mg once daily plus darolutamide in post-abiraterone metastatic castration-resistant prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results